FBRX – Forte Biosciences Inc
Forte Biosciences, Inc.FBRX
$12.25Name : Forte Biosciences, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $80,646,408.00
EPSttm : -9.51
Forte Biosciences, Inc.
$12.25
7.36%$0.84Float Short %
3.11
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.26
EPS Last/This Y
7.52
EPS This/Next Y
1.2
Price
12.1
Target Price
48.67
Analyst Recom
1
Performance Q
54.87
Relative Volume
4.49
Beta
2.91
Ticker: FBRX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | FBRX | 8.93 | N/A | N/A | 0 |
| 2025-06-03 | FBRX | 9.58 | N/A | N/A | 0 |
| 2025-06-04 | FBRX | 10.05 | N/A | N/A | 0 |
| 2025-06-05 | FBRX | 10.37 | N/A | N/A | 0 |
| 2025-06-06 | FBRX | 11.45 | N/A | N/A | 0 |
| 2025-06-09 | FBRX | 11.85 | N/A | N/A | 0 |
| 2025-06-10 | FBRX | 12.21 | N/A | N/A | 0 |
| 2025-06-11 | FBRX | 12.67 | N/A | N/A | 0 |
| 2025-06-12 | FBRX | 12.78 | N/A | N/A | 0 |
| 2025-06-13 | FBRX | 12.14 | N/A | N/A | 0 |
| 2025-06-16 | FBRX | 13.6 | N/A | N/A | 0 |
| 2025-06-17 | FBRX | 12.62 | N/A | N/A | 0 |
| 2025-06-18 | FBRX | 12.37 | N/A | N/A | 0 |
| 2025-06-20 | FBRX | 13.66 | N/A | N/A | 0 |
| 2025-06-23 | FBRX | 12.75 | N/A | N/A | 0 |
| 2025-06-24 | FBRX | 14.47 | N/A | N/A | 0 |
| 2025-06-25 | FBRX | 11.27 | N/A | N/A | 0 |
| 2025-06-26 | FBRX | 11.36 | N/A | N/A | 0 |
| 2025-06-27 | FBRX | 12.13 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | FBRX | 8.79 | 80.9 | - | -4.93 |
| 2025-06-03 | FBRX | 9.55 | 80.9 | - | -4.93 |
| 2025-06-04 | FBRX | 9.98 | 80.9 | - | -4.93 |
| 2025-06-05 | FBRX | 10.35 | 80.9 | - | -4.93 |
| 2025-06-06 | FBRX | 11.11 | 80.9 | - | -4.65 |
| 2025-06-09 | FBRX | 11.95 | 82.5 | - | -4.65 |
| 2025-06-10 | FBRX | 12.03 | 82.5 | - | -4.65 |
| 2025-06-11 | FBRX | 12.60 | 82.5 | - | -4.65 |
| 2025-06-12 | FBRX | 12.54 | 82.5 | - | -4.65 |
| 2025-06-13 | FBRX | 12.01 | 82.5 | - | -4.65 |
| 2025-06-16 | FBRX | 13.02 | 82.5 | - | -4.65 |
| 2025-06-17 | FBRX | 12.57 | 82.5 | - | -4.65 |
| 2025-06-18 | FBRX | 12.44 | 82.5 | - | -4.65 |
| 2025-06-20 | FBRX | 14.66 | 82.5 | - | -4.65 |
| 2025-06-23 | FBRX | 12.75 | 82.5 | - | -4.65 |
| 2025-06-24 | FBRX | 14.46 | 82.5 | - | -4.65 |
| 2025-06-25 | FBRX | 11.53 | 82.5 | - | -4.65 |
| 2025-06-26 | FBRX | 11.30 | 82.5 | - | -4.65 |
| 2025-06-27 | FBRX | 12.10 | 82.5 | - | -4.65 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | FBRX | 0.00 | -8.99 | 2.43 |
| 2025-06-03 | FBRX | 0.00 | -8.99 | 2.43 |
| 2025-06-04 | FBRX | 0.00 | -8.99 | 2.43 |
| 2025-06-05 | FBRX | 0.00 | -8.99 | 2.43 |
| 2025-06-06 | FBRX | 0.00 | -8.99 | 2.43 |
| 2025-06-09 | FBRX | 0.00 | -8.99 | 2.43 |
| 2025-06-11 | FBRX | 0.00 | -8.99 | 3.25 |
| 2025-06-12 | FBRX | 0.00 | -8.99 | 3.25 |
| 2025-06-13 | FBRX | 0.00 | -8.99 | 3.25 |
| 2025-06-16 | FBRX | 0.00 | -8.94 | 3.25 |
| 2025-06-17 | FBRX | 0.00 | -8.94 | 3.25 |
| 2025-06-18 | FBRX | 0.00 | -8.94 | 3.25 |
| 2025-06-19 | FBRX | 0.00 | -8.94 | 3.25 |
| 2025-06-20 | FBRX | 0.00 | -8.94 | 3.25 |
| 2025-06-24 | FBRX | 0.00 | -8.99 | 3.25 |
| 2025-06-25 | FBRX | 0.00 | -8.99 | 3.25 |
| 2025-06-26 | FBRX | 0.00 | -8.99 | 3.11 |
| 2025-06-27 | FBRX | 0.00 | -8.99 | 3.11 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.37
Avg. EPS Est. Current Quarter
-1.18
Avg. EPS Est. Next Quarter
-1.11
Insider Transactions
Institutional Transactions
-8.99
Beta
2.91
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
7
Growth Score
21
Sentiment Score
10
Actual DrawDown %
99.1
Max Drawdown 5-Year %
-99.7
Target Price
48.67
P/E
Forward P/E
PEG
P/S
P/B
2.1
P/Free Cash Flow
EPS
-13.81
Average EPS Est. Cur. Y
-4.65
EPS Next Y. (Est.)
-3.45
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
4.49
Return on Equity vs Sector %
-137.7
Return on Equity vs Industry %
-119.8
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
-1.06
EBIT Estimation
Forte Biosciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 14
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
stock quote shares FBRX – Forte Biosciences Inc Stock Price stock today
news today FBRX – Forte Biosciences Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FBRX – Forte Biosciences Inc yahoo finance google finance
stock history FBRX – Forte Biosciences Inc invest stock market
stock prices FBRX premarket after hours
ticker FBRX fair value insiders trading